Tahereh Ghaziani

ORCID: 0000-0002-2652-0595
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Liver Disease Diagnosis and Treatment
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Liver Disease and Transplantation
  • Hepatitis B Virus Studies
  • Hepatitis C virus research
  • Liver Diseases and Immunity
  • Organ Transplantation Techniques and Outcomes
  • Neonatal Health and Biochemistry
  • Hepatitis Viruses Studies and Epidemiology
  • Folate and B Vitamins Research
  • Alcohol Consumption and Health Effects
  • Renal Transplantation Outcomes and Treatments
  • Molecular Biology Techniques and Applications
  • Heme Oxygenase-1 and Carbon Monoxide
  • Celiac Disease Research and Management
  • Gastrointestinal disorders and treatments
  • Viral-associated cancers and disorders
  • Metabolism and Genetic Disorders
  • Iron Metabolism and Disorders
  • Radiomics and Machine Learning in Medical Imaging
  • Artificial Intelligence in Healthcare and Education
  • Colorectal Cancer Screening and Detection
  • Helminth infection and control
  • Polyomavirus and related diseases
  • Optimism, Hope, and Well-being

Stanford University
2020-2025

Stanford Medicine
2020-2022

Beth Israel Deaconess Medical Center
2012-2018

Specifica (United States)
2017

Harvard University
2016

Cambridge Hospital
2007

Shahid Beheshti University
2007

UConn Health
2004-2006

Shahid Beheshti University of Medical Sciences
2004-2005

Mashhad University of Medical Sciences
2004

ChatGPT did not reliably provide accurate information to 20 questions about liver cancer surveillance and diagnosis, as assessed by six physicians who actively diagnose and/or treat cancer. Answers deemed inaccurate commonly related on specific LI-RADS categories included contradictory or falsely reassuring, if wrong, information.

10.2214/ajr.23.29493 article EN American Journal of Roentgenology 2023-05-24

Summary Background Recent animal studies have shown that platelets directly activate hepatic stellate cells to promote liver fibrosis, whereas anti‐platelet agents decrease fibrosis. It is unknown whether platelet inhibition by aspirin prevents fibrosis in humans. Aim To examine the association between use and among adults with suspected chronic disease. Methods We conducted a cross‐sectional analysis using data from National Health Nutrition Examination Survey III . identified 1856...

10.1111/apt.13515 article EN Alimentary Pharmacology & Therapeutics 2016-01-07

Background: Patients with cirrhosis and subcentimeter lesions on liver ultrasound are recommended to undergo short-interval follow-up because of the presumed low risk primary cancer (PLC). Aims: The aim this study is characterize recall patterns PLC in patients ultrasound. Methods: We conducted a multicenter retrospective cohort among or chronic hepatitis B infection who had between January 2017 December 2019. excluded history concomitant ≥1 cm diameter. used Kaplan Meier multivariable Cox...

10.1097/hc9.0000000000000073 article EN cc-by-nc-nd Hepatology Communications 2023-03-01

Patients with hepatocellular carcinoma (HCC) meeting UNOS-downstaging (DS) criteria have excellent post-liver transplantation (LT) outcomes. Studies on HCC beyond UNOS-DS ("All-comers" (AC)) been limited by small sample size and short follow-up time, prompting this analysis. 326 patients 190 AC from 9 LT centers across 5 UNOS regions were enrolled 2015 to 2023 prospectively followed. Competing risk analysis Kaplan-Meier method used evaluate downstaging outcomes, Fine-and-Gray Cox models...

10.1097/hep.0000000000001231 article EN Hepatology 2025-01-14

Heme oxygenase-1 is an antioxidant defense enzyme that converts heme to biliverdin, iron, and carbon monoxide. Bach-1 a bZip protein forms heterodimers with small Maf proteins was reported recently down-regulate the HO-1 gene in mice. Using interfering RNAs targeted human mRNA, we investigated whether modulation of hepatic expression by (si)RNA technology influences expression. We found siRNAs transfected into Huh-7 cells significantly reduced mRNA levels ∼80%, compared non siRNA-treated...

10.1074/jbc.m409463200 article EN cc-by Journal of Biological Chemistry 2004-12-01

Abstract Therapies for primary liver cancer, the third leading cause of cancer-related death worldwide, remain limited. Following multi-omics analysis (including whole genome and transcriptome sequencing), we were able to identify dual-specific protein kinase TTK as a putative new prognostic biomarker cancer. Herein, show that levels are significantly elevated in neoplastic tissues from cohort cancer patients, when compared with adjacent hepatic tissues. We also tested utility targeted...

10.1038/srep33121 article EN cc-by Scientific Reports 2016-09-13

Patients with hepatocellular carcinoma meeting united network for organ sharing (UNOS)-downstaging (DS) criteria have excellent liver transplantation (LT) outcomes after DS. However, "all-comers" (AC) patients tumors initially exceeding UNOS-DS are poorly understood. AC (n = 82) or 229) at 7 LT centers in 4 UNOS regions were prospectively followed from 2015-2020. had a lower probability of successful DS (67% vs 83% within 12 months; P < .001). The 3-year survival was 69% 58% (P .05) and...

10.1016/j.ajt.2023.07.021 article EN cc-by-nc-nd American Journal of Transplantation 2023-07-31

We tested associations between HFE mutations and hepatitis B virus (HBV) infection. also explored measures of total body iron status their association with chronic HBV infection.Serum (C282Y, H63D, S65C) were assessed in 344 Iranian patients infection (214 asymptomatic carriers, 130 progressive liver disease [CPLD]) 302 controls.Frequencies did not differ controls (C282Y: P=0.9, H63D: P= 0.8, S65C: P=0.9). By logistic regression, advanced hepatic fibrosis was associated H63D mutation...

10.1111/j.1872-034x.2007.00026.x article EN Hepatology Research 2007-03-01

Abstract Chronic hepatitis B virus (HBV) infection is the leading risk factor for hepatocellular carcinoma (HCC). The aim of this study was to explore incidence HCC in a cohort subjects with HBV and correlate treatment current guidance. We identified 2846 over period. diagnosed 386 (14%) subjects; 209 (54%) were on nucleos(t)ide analogue (NA) therapy at time diagnosis, 177 (46%) not NA therapy. Of NAs who developed during follow‐up, 153 (86%) had cirrhosis. Within NAs, 158 (89%) undetectable...

10.1002/hep4.2064 article EN Hepatology Communications 2022-08-25

Fasciola hepatica primarily involves the liver, however in some exceptional situations other organs have been reported to be involved. The ectopic involvement is either a result of Parasite migration or perhaps eosinophilic reaction.Here we report known case multiple myeloma who was under treatment with prednisolone and melphalan. He infected by hepatica, which involved many lesions were mistaken metastatic ones.Presented here very unusual disease, likely first involving pancreas, spleen,...

10.1186/1471-230x-4-15 article EN cc-by BMC Gastroenterology 2004-08-04

10.1007/s11938-021-00346-x article EN Current Treatment Options in Gastroenterology 2021-03-31

Abstract Background Malignancy-related ascites accounts for approximately 10% of causes ascites. Our AIM was to characterize the fluid and correlate clinical outcomes in those with extrahepatic malignancy Methods 241 subjects solid tumors were reviewed from 1/1/2000 12/31/2019, 119 without liver metastasis 122 metastasis. Results Ascites consistent peritoneal carcinomatosis (PC) most common, 150/241 (62%), followed by reflecting presence portal hypertension (PH), 69/241 (29%). 22/241 (9%)...

10.1186/s12876-022-02487-4 article EN cc-by BMC Gastroenterology 2022-09-05

In this study, the frequencies of common hemochromatosis gene mutations were assessed in 75 Iranian subjects with chronic hepatitis B infection. We found that major C282Y mutation was significantly more frequent infected virus (4%) than 194 control (0%, P = .02; Fisher's exact test).

10.1086/426143 article EN Clinical Infectious Diseases 2005-02-01

The incidence of hepatocellular carcinoma (HCC) is growing in the United States, especially among elderly. Older patients are increasingly receiving transplants as a result HCC, but impact advancing age on long-term posttransplant outcomes not clear. To study this, we used data from US Multicenter HCC Transplant Consortium 4980 patients. We divided into 4 groups by at transplantation: 18 to 64 years (n = 4001), 65 69 683), 70 74 252), and ≥75 44). There were no differences tumor stage, type...

10.1002/lt.25974 article EN Liver Transplantation 2020-12-11

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by authors. Any queries (other than missing content) should be directed to corresponding author article.

10.1002/lt.26373 article EN Liver Transplantation 2021-11-22
Coming Soon ...